A substantial advancement in glucose care is emerging with the release of tirzepatide at a dosage of 45mg. This new formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 receptor, and https://utherpeptidess.com/product/tirzepatide-45mg/